NCT06793163

Brief Summary

Perioperative anaphylaxis may lead to fatal respiratory and/or circulatory events, yet both clinical diagnosis and management are challenging. Serum tryptase is an indicator that can provide important retrospective diagnostic value for anaphylaxis. Another key point in perioperative anaphylaxis management is to identify the allergens, and thus avoid re-exposure during later perioperative management. Skin testing is an important way to identify allergens.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
115

participants targeted

Target at P50-P75 for all trials

Timeline
19mo left

Started Jan 2025

Typical duration for all trials

Geographic Reach
1 country

5 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress45%
Jan 2025Dec 2027

First Submitted

Initial submission to the registry

January 20, 2025

Completed
5 days until next milestone

Study Start

First participant enrolled

January 25, 2025

Completed
2 days until next milestone

First Posted

Study publicly available on registry

January 27, 2025

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2027

Last Updated

November 24, 2025

Status Verified

November 1, 2025

Enrollment Period

2.8 years

First QC Date

January 20, 2025

Last Update Submit

November 19, 2025

Conditions

Keywords

Perioperative/Postoperative ComplicationsAnaphylaxisTryptaseAllergensSkin Testing

Outcome Measures

Primary Outcomes (1)

  • Incidence of severe perioperative anaphylaxis

    Perioperative anaphylaxis is defined as anaphylaxis that is confirmed by clinical signs and symptoms and changes of serum tryptase level according to the World Allergy Organization Anaphylaxis Guidance 2020 and occurred in the operating room. Severe perioperative anaphylaxis indicates grade 3 or above according to the World Allergy Organization systemic allergic reaction grading system. The incidence is calculated as the number of cases with severe perioperative anaphylaxis divided by the total number of cases who undergo surgery in the operating room during the study period.

    On the day of surgery in the operating room

Secondary Outcomes (3)

  • Diagnostic rate of anaphylaxis in patients with suspected perioperative anaphylaxis.

    On the day of surgery in the operating room

  • Incidence of perioperative anaphylaxis

    On the day of surgery in the operating room

  • Allergen detection in patients with perioperative anaphlaxis

    At least 4-6 weeks after the confirmed perioperative anaphylaxis

Other Outcomes (3)

  • Rate of surgical suspension due to suspected perioperative anaphylaxis.

    On the day of surgery suspected perioperative anaphylaxis

  • Rate of unplanned ICU admission due to suspected perioperative anaphylaxis

    Within 24 hours of suspected perioperative anaphylaxis

  • Rate of recurrence of perioperative anaphylaxis

    On the day of surgery in the operating room

Study Arms (1)

Suspected anaphylaxis

Adult patients with suspected anaphylaxis in the operating rooms, or with history of suspected anaphylaxis in the operating room.

Eligibility Criteria

Age2 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with suspected anaphylaxis in the operating room.

You may qualify if:

  • Aged 2 years or over;
  • Suspected anaphylaxis in the operating rooms, or history of suspected anaphylaxis in the operating room.

You may not qualify if:

  • Refuse to participate;
  • Other conditions that are considered unsuitable for study participation.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

Peking University First Hospital

Beijing, Beijing Municipality, 100034, China

RECRUITING

Beijing Anorectal Hospital (Beijing Erlong Road Hospital)

Beijing, Beijing Municipality, China

RECRUITING

Beijing Children's Hospital, Capital Medical University; National Center for Children's Health, China

Beijing, Beijing Municipality, China

RECRUITING

Beijing Friendship Hospital, Capital Medical University

Beijing, Beijing Municipality, China

RECRUITING

Peking University First Hospital

Beijing, Beijing Municipality, China

RECRUITING

Related Publications (3)

  • Muraro A, Worm M, Alviani C, Cardona V, DunnGalvin A, Garvey LH, Riggioni C, de Silva D, Angier E, Arasi S, Bellou A, Beyer K, Bijlhout D, Bilo MB, Bindslev-Jensen C, Brockow K, Fernandez-Rivas M, Halken S, Jensen B, Khaleva E, Michaelis LJ, Oude Elberink HNG, Regent L, Sanchez A, Vlieg-Boerstra BJ, Roberts G; European Academy of Allergy and Clinical Immunology, Food Allergy, Anaphylaxis Guidelines Group. EAACI guidelines: Anaphylaxis (2021 update). Allergy. 2022 Feb;77(2):357-377. doi: 10.1111/all.15032. Epub 2021 Sep 1.

    PMID: 34343358BACKGROUND
  • Tran R, Pedersen K, Kolawole H, Roessler P, Scolaro R. Australian and New Zealand Anaesthetic Allergy Group/Australian and New Zealand College of Anaesthetists perioperative anaphylaxis management guideline 2022. Anaesth Intensive Care. 2024 May;52(3):147-158. doi: 10.1177/0310057X231215823. Epub 2024 Apr 8.

    PMID: 38587791BACKGROUND
  • Manian DV, Volcheck GW. Perioperative Anaphylaxis: Evaluation and Management. Clin Rev Allergy Immunol. 2022 Jun;62(3):383-399. doi: 10.1007/s12016-021-08874-1. Epub 2021 Jul 10.

    PMID: 34247332BACKGROUND

Biospecimen

Retention: SAMPLES WITHOUT DNA

Serum

MeSH Terms

Conditions

Postoperative ComplicationsAnaphylaxis

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and SymptomsHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Study Officials

  • Dong-Xin Wang, MD, PhD

    Peking University First Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Dong-Xin Wang, MD, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Chairman of Department of Anesthesiology

Study Record Dates

First Submitted

January 20, 2025

First Posted

January 27, 2025

Study Start

January 25, 2025

Primary Completion (Estimated)

December 1, 2027

Study Completion (Estimated)

December 1, 2027

Last Updated

November 24, 2025

Record last verified: 2025-11

Locations